An impact of pronoran on cognitive and affective disorders in Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 105, Issue 4, 2005, Pages 41-47

  Pilipovich, A A ^a   Golubev, V L ^a  

^a NONE

Author keywords

Parkinson's disease; Pronoran; Treatment

Indexed keywords

ANTIPARKINSON AGENT; DRUG DERIVATIVE; PIRIBEDIL;

ADULT; AFFECT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREMOR;

ADULT; AFFECT; AGED; ANTIPARKINSON AGENTS; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PIRIBEDIL; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 19844370019     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cagnotto A., Parotti L., Mennini T. In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study. Eur J Pharmacol 1996; 10: 63-67.
2. Corradino et al. Trivastal retard 50 in everyday medical practice. Its value in the treatment of dizziness, tinnitus and memory disorders. Trib Med 1988; 3: 39-42.
3. Cummings J.L. Depression and Parkinson disease: a review. Am J Psychiat 1992; 149: 443-454.
4. Dubois B., Pillon B. Dementia in Parkinson's disease. Mental disfunction in Parkinson's Disease II. Current issues in neurodegenerative diseases. Academic Pharmaceutical Productions. Utrecht (Netherlands) 1999; 165-176.
5. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical guide for grading the mental state of patients for the clinician. J Psych Res 1975; 12: 189-198.
6. Jenner P. Piribedil induces low levels of dyskinesia in MPTP - treated common marmoset. Abstract of 52 Annual Meeting of the American Academy of Neurology. San Diego 2000.
7. Kahvecioglu U., Özkaynak S., Zadikoglu A. et al. Efficacy of piribedil on age - related cognitive decline. Med J Akdeniz University Cilt 1995; 12: 1-3: 1300-1779.
8. Knopman D. Long-term retention of implicitly acquired learning in patients with Alzheimer's disease. J Clin Exp Neuropsychol 1991; 6: 880-894.
9. Millan M.J., Cussac D., Milligan G. et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 2001; 297: 3: 876-887.
10. Nagaraja D., Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiat 2001; 9: 1517-1519.
11. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol 1992; S13-16.
12. Perry R., McKeith J., Perry E. Dementia with lewy bodies. Clinical, pathological and treatment issues. Cambridge 1996.
13. Smith L.A., Jackson M.G., Bonhomme C. et al. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 2000; 23: 133-142.
14. Tolosa E. Dopamine levodopa-induced dyskinesias and fluctuations in Parkinson's disease. Barcelona 1999.
15. Watts R.L. The role of dopamine agonists in early Parkinson's disease. Neurology 1997; 49: 34-48.
16. Ziegler M., Rondot P. Activity of piribedil in Parkinson's disease: a multicenter study. Presse Med 1999; 28: 1414-1418.
17. Ziegler M., Caldas A., Del Signore et al. Efficacy of piribedil in acinetic-hypertonic Parkinsonian patients after 4-month combination treatment with L-Dopa. Parkinsonism and related disorders 2001; 7: 75.